Enliven Historical Financial Ratios
| ELVN Stock | 24.54 0.87 3.42% |
Enliven Therapeutics is recently reporting on over 81 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 2.1 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Enliven Therapeutics financial condition quickly.
Enliven |
About Enliven Financial Ratios Analysis
Enliven TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Enliven Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Enliven financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Enliven Therapeutics history.
Enliven Therapeutics Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Average Inventory
The average amount of inventory a company holds over a certain period, which is used to calculate inventory turnover and efficiency in managing stock levels.Most ratios from Enliven Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Current Ratio is very stable compared to the past year. As of the 25th of November 2024, Tangible Book Value Per Share is likely to grow to 7.26, while Free Cash Flow Yield is likely to drop (0.13).
Enliven Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Enliven Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enliven Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (5.31) | (15.12) | (1.64) | (1.33) | 2.0 | 2.1 | |
| Book Value Per Share | 6.69 | (5.83) | (5.49) | (12.29) | 6.92 | 7.26 | |
| Free Cash Flow Yield | (0.0849) | (0.0293) | (0.27) | (0.32) | (0.12) | (0.13) | |
| Pb Ratio | (5.31) | (15.12) | (1.64) | (1.33) | 2.0 | 2.1 | |
| Free Cash Flow Per Share | (5.1) | (2.58) | (2.47) | (5.23) | (1.73) | (1.81) | |
| Net Income Per Share | (5.43) | (5.44) | (3.16) | (6.04) | (2.01) | (2.11) | |
| Cash Per Share | 6.69 | 49.09 | 19.45 | 12.09 | 7.12 | 11.25 | |
| Pocfratio | (11.85) | (36.0) | (3.68) | (3.19) | (8.03) | (8.43) | |
| Pfcf Ratio | (11.77) | (34.15) | (3.64) | (3.13) | (8.01) | (8.41) | |
| Roe | 0.48 | 0.93 | 0.58 | 0.49 | (0.29) | (0.28) | |
| Ev To Operating Cash Flow | (11.62) | (20.73) | 2.07 | (0.84) | (6.4) | (6.72) | |
| Pe Ratio | (11.05) | (16.22) | (2.85) | (2.71) | (6.87) | (7.22) | |
| Return On Tangible Assets | (0.7) | (0.14) | (0.22) | (0.45) | (0.26) | (0.28) | |
| Ev To Free Cash Flow | (11.55) | (19.66) | 2.05 | (0.83) | (6.38) | (6.7) | |
| Net Debt To E B I T D A | 0.21 | 14.05 | 4.46 | 1.95 | 1.22 | 1.28 | |
| Current Ratio | 7.29 | 88.35 | 19.24 | 8.0 | 10.28 | 17.11 | |
| Tangible Book Value Per Share | 6.69 | (5.83) | (5.49) | (12.29) | 6.92 | 7.26 | |
| Graham Number | 37.17 | 26.72 | 19.76 | 40.88 | 17.7 | 29.56 | |
| Shareholders Equity Per Share | (11.31) | (5.83) | (5.49) | (12.29) | 6.92 | 7.26 | |
| Graham Net Net | 5.68 | 5.63 | (0.54) | (13.54) | 6.39 | 6.71 | |
| Enterprise Value Over E B I T D A | (10.85) | (19.06) | 1.6 | (0.7) | (4.79) | (4.55) | |
| Price Earnings Ratio | (11.05) | (16.22) | (2.85) | (2.71) | (6.87) | (7.22) | |
| Price Book Value Ratio | (5.31) | (15.12) | (1.64) | (1.33) | 2.0 | 2.1 | |
| Price To Operating Cash Flows Ratio | (11.85) | (36.0) | (3.68) | (3.19) | (8.03) | (8.43) | |
| Price To Free Cash Flows Ratio | (11.77) | (34.15) | (3.64) | (3.13) | (8.01) | (8.41) | |
| Ebt Per Ebit | 1.06 | 0.97 | 2.04 | 1.0 | 0.86 | 0.78 | |
| Effective Tax Rate | (0.0278) | 0.001635 | 8.89E-4 | (0.002337) | (0.002687) | (0.002553) | |
| Company Equity Multiplier | (0.68) | (6.45) | (2.64) | (1.08) | 1.11 | 1.16 | |
| Return On Capital Employed | (0.83) | (0.0719) | (0.23) | (0.53) | (0.34) | (0.36) |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.84 | VCNX | Vaccinex | PairCorr |
| 0.72 | GMAB | Genmab AS | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.61 | LEGN | Legend Biotech Corp | PairCorr |
| 0.59 | KRYS | Krystal Biotech | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.